Description
Reta (development code LY3437943) is a synthetic linear peptide designed as a triple agonist of the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors.
-
Backbone: It is a 39–amino acid peptide, structurally engineered from the native GIP sequence as its base scaffold.
-
Modifications:
-
Strategic amino acid substitutions enhance stability against enzymatic degradation (particularly by DPP-IV).
-
A C-terminal extension includes a fatty acid side chain (C20 diacid) conjugated via a linker to promote strong albumin binding, thereby extending half-life.
-
-
Conformation: These modifications maintain the peptide’s affinity for the GLP-1R, GIPR, and GCGR while prolonging systemic exposure and reducing clearance.
PLEASE NOTE THAT ALL PRODUCTS FEATURED HERE ARE INTENDED EXCLUSIVELY FOR RESEARCH AND DEVELOPMENT PURPOSES. THEY ARE NOT DESIGNED FOR ANY FORM OF HUMAN CONSUMPTION. THESE PRODUCTS HAVE NOT UNDERGONE EVALUATION BY THE U.S. FOOD AND DRUG ADMINISTRATION.
